RxDoctor Payments Data

Heather Bragg, NP

Family · Christiansburg, VANPI 1992181226

Payments from drug & device makers

$7,429in general payments, 2019–2025

Across 515 payments — averaging $14.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$965
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$808
  • Lundbeck LLC$708
  • Neurocrine Biosciences, Inc.$474
  • Supernus Pharmaceuticals, Inc.$410
  • E.r. Squibb & Sons, L.L.C.$358
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$7,34499%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,429 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$3,836
Medicare patients
12
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate34$266,949
Invega SustennaPaliperidone Palmitate14$49,483
VraylarCariprazine Hcl27$37,928
CaplytaLumateperone Tosylate20$32,323
TrintellixVortioxetine Hydrobromide16$7,705
BelsomraSuvorexant12$5,367
Lisdexamfetamine Dimesylate19$4,983
Lamotrigine ErLamotrigine22$3,879
Venlafaxine Hcl ErVenlafaxine Hcl53$2,184
Fluvoxamine Maleate ErFluvoxamine Maleate11$1,820
Aripiprazole13$1,734
Desvenlafaxine Succinate ErDesvenlafaxine Succinate29$1,169
Bupropion XlBupropion Hcl70$1,071
Methylphenidate ErMethylphenidate Hcl17$801
Methylphenidate Hcl13$752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$474$266,94934 claims
Johnson & JohnsonInvega Sustenna$350$49,48314 claims
AbbVieVraylar$965$37,92827 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$808$32,32320 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$151$7,70516 claims
MerckBelsomra$66$5,36712 claims
Lilly USA, LLCOlanzapine$300$53939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Christiansburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →